494 related articles for article (PubMed ID: 32335126)
1. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
2. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
3. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
4. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
5. SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Mainardi S; Mulero-Sánchez A; Prahallad A; Germano G; Bosma A; Krimpenfort P; Lieftink C; Steinberg JD; de Wit N; Gonçalves-Ribeiro S; Nadal E; Bardelli A; Villanueva A; Bernards R
Nat Med; 2018 Jul; 24(7):961-967. PubMed ID: 29808006
[TBL] [Abstract][Full Text] [Related]
6. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
7. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
8. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
10. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
11. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
Dai X; Xia H; Zhou S; Tang Q; Bi F
Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
[TBL] [Abstract][Full Text] [Related]
13.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
14. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Kerr DL; Haderk F; Bivona TG
Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
[TBL] [Abstract][Full Text] [Related]
15. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
16.
Seo H; Song J; Kim M; Han DW; Park HJ; Song M
Nutrients; 2018 Dec; 11(1):. PubMed ID: 30577618
[No Abstract] [Full Text] [Related]
17. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
Song Q; Sun X; Guo H; Yu Q
Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
[TBL] [Abstract][Full Text] [Related]
18. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
[TBL] [Abstract][Full Text] [Related]
19. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract][Full Text] [Related]
20. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
